Cargando…
The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer
BACKGROUND: Adjuvant durvalumab after chemoradiation has become the standard of care for patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before durvalumab for patients with stage III NSCLC showed predictive and prognostic effects remains unknown. METHODS: This is a...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101664/ https://www.ncbi.nlm.nih.gov/pubmed/37043179 http://dx.doi.org/10.1080/07853890.2023.2196089 |
_version_ | 1785025557611675648 |
---|---|
author | Matsuura, Shun Serizawa, Sayaka Yamashita, Ryoma Morikawa, Keisuke Ito, Yutaro Hiramatsu, Toshiya Mochizuki, Eisuke Tanaka, Kazuki Akiyama, Norimichi Tsukui, Masaru Koshimizu, Naoki Kosugi, Takashi |
author_facet | Matsuura, Shun Serizawa, Sayaka Yamashita, Ryoma Morikawa, Keisuke Ito, Yutaro Hiramatsu, Toshiya Mochizuki, Eisuke Tanaka, Kazuki Akiyama, Norimichi Tsukui, Masaru Koshimizu, Naoki Kosugi, Takashi |
author_sort | Matsuura, Shun |
collection | PubMed |
description | BACKGROUND: Adjuvant durvalumab after chemoradiation has become the standard of care for patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before durvalumab for patients with stage III NSCLC showed predictive and prognostic effects remains unknown. METHODS: This is a retrospective study in the Fujieda Municipal General Hospital between October 2018 and March 2022. We assessed the predictive value of the Prognostic Nutritional Index (PNI) in stage III non-small cell lung cancer (NSCLC) patients treated with durvalumab after chemoradiation. RESULTS: After applying the inclusion and exclusion criteria, the study included 56 patients for further analysis. The median follow-up period was 17.6 months (range, 3.0–45.4 months). According to receiver operating characteristic curve results, the PNI cutoff value to predict overall survival (OS) was 37.9, with sensitivity and specificity at 67.9% and 67.9%. Accordingly, the patients were divided into low- and high-PNI groups. Patients with the low-PNI group had a significantly shorter progression-free survival compared to the high-PNI group (median, 9.1 vs. 21.3 months, p = 0.032). OS was also shorter in the low-PNI group (median, 19.0 months vs. not reached, p < 0.001). In the multivariate Cox hazards regression analyses, the high-PNI was an independent prognostic factor for OS (hazard ratio, 0.187; 95% confidence interval, 0.046–0.760; p = 0.019). CONCLUSIONS: It seems that PNI could be used as a predictor for OS in patients with stage III NSCLC treated with durvalumab after chemoradiation. KEY MESSAGES: Inadequate immunocompetence and nutritional status after chemoradiation therapy may result in poor antitumor efficacy of ICIs. Pretreatment immune and nutritional assessment using PNI could be considered an independent predictor for the survival of stage III NSCLC patients treated with durvalumab after chemoradiation therapy. |
format | Online Article Text |
id | pubmed-10101664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-101016642023-04-14 The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer Matsuura, Shun Serizawa, Sayaka Yamashita, Ryoma Morikawa, Keisuke Ito, Yutaro Hiramatsu, Toshiya Mochizuki, Eisuke Tanaka, Kazuki Akiyama, Norimichi Tsukui, Masaru Koshimizu, Naoki Kosugi, Takashi Ann Med Oncology BACKGROUND: Adjuvant durvalumab after chemoradiation has become the standard of care for patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before durvalumab for patients with stage III NSCLC showed predictive and prognostic effects remains unknown. METHODS: This is a retrospective study in the Fujieda Municipal General Hospital between October 2018 and March 2022. We assessed the predictive value of the Prognostic Nutritional Index (PNI) in stage III non-small cell lung cancer (NSCLC) patients treated with durvalumab after chemoradiation. RESULTS: After applying the inclusion and exclusion criteria, the study included 56 patients for further analysis. The median follow-up period was 17.6 months (range, 3.0–45.4 months). According to receiver operating characteristic curve results, the PNI cutoff value to predict overall survival (OS) was 37.9, with sensitivity and specificity at 67.9% and 67.9%. Accordingly, the patients were divided into low- and high-PNI groups. Patients with the low-PNI group had a significantly shorter progression-free survival compared to the high-PNI group (median, 9.1 vs. 21.3 months, p = 0.032). OS was also shorter in the low-PNI group (median, 19.0 months vs. not reached, p < 0.001). In the multivariate Cox hazards regression analyses, the high-PNI was an independent prognostic factor for OS (hazard ratio, 0.187; 95% confidence interval, 0.046–0.760; p = 0.019). CONCLUSIONS: It seems that PNI could be used as a predictor for OS in patients with stage III NSCLC treated with durvalumab after chemoradiation. KEY MESSAGES: Inadequate immunocompetence and nutritional status after chemoradiation therapy may result in poor antitumor efficacy of ICIs. Pretreatment immune and nutritional assessment using PNI could be considered an independent predictor for the survival of stage III NSCLC patients treated with durvalumab after chemoradiation therapy. Taylor & Francis 2023-04-12 /pmc/articles/PMC10101664/ /pubmed/37043179 http://dx.doi.org/10.1080/07853890.2023.2196089 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Oncology Matsuura, Shun Serizawa, Sayaka Yamashita, Ryoma Morikawa, Keisuke Ito, Yutaro Hiramatsu, Toshiya Mochizuki, Eisuke Tanaka, Kazuki Akiyama, Norimichi Tsukui, Masaru Koshimizu, Naoki Kosugi, Takashi The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer |
title | The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer |
title_full | The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer |
title_fullStr | The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer |
title_full_unstemmed | The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer |
title_short | The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer |
title_sort | prognostic nutritional index before durvalumab after chemoradiation predict the overall survival in patients with stage iii non-small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101664/ https://www.ncbi.nlm.nih.gov/pubmed/37043179 http://dx.doi.org/10.1080/07853890.2023.2196089 |
work_keys_str_mv | AT matsuurashun theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT serizawasayaka theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT yamashitaryoma theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT morikawakeisuke theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT itoyutaro theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT hiramatsutoshiya theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT mochizukieisuke theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT tanakakazuki theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT akiyamanorimichi theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT tsukuimasaru theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT koshimizunaoki theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT kosugitakashi theprognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT matsuurashun prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT serizawasayaka prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT yamashitaryoma prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT morikawakeisuke prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT itoyutaro prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT hiramatsutoshiya prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT mochizukieisuke prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT tanakakazuki prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT akiyamanorimichi prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT tsukuimasaru prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT koshimizunaoki prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer AT kosugitakashi prognosticnutritionalindexbeforedurvalumabafterchemoradiationpredicttheoverallsurvivalinpatientswithstageiiinonsmallcelllungcancer |